Sanofi invests 20 billion dollars in the USA: jobs in focus!

Sanofi invests 20 billion dollars in the USA: jobs in focus!

Sanofi, the largest European pharmaceutical company, has announced that it will invest at least $20 billion (17.88 billion euros) in the USA by 2030. The goal of these major investments is to increase research and development spending and production capacity in the United States. These measures are intended not only to strengthen the company, but also to create a significant number of well-paying jobs in several states. Sanofi's investment decisions are flexibly adapted to the development of the external environment to ensure maximum efficiency and benefits MarketScreener reported.

A significant portion of Sanofi's net sales comes from pharmaceutical products, which account for 79.8% of total sales. Of this, 63.2% is specialized medicine and 36.8% is general medicine. In addition, human vaccines contribute 20.2% to sales. In terms of geographical distribution of net sales, the US is the most important region for Sanofi with 48.7%, followed by Europe with 17.6% and France with 4.4%.

Research and development in focus

Sanofi is not only investing in production capacity, but also increasingly in research and development. According to information from Sanofi The company's goal is to develop innovative therapies and solutions that improve the health of patients worldwide. This strategic direction is crucial to meet the ever-changing needs of the healthcare sector.

With already 52 production sites worldwide by the end of 2024, Sanofi is well positioned to master the economic and social challenges of the coming years. The decision to classify the consumer healthcare products business (Opella) as a discontinued operation also shows the company's clear focus on its core competencies. This is in line with the planned billions of dollars in spending in the USA, which are also intended to bring potentially new products and technologies to market maturity.